IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v19y2021i3d10.1007_s40258-020-00623-3.html
   My bibliography  Save this article

Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C

Author

Listed:
  • Pingyu Chen

    (China Pharmaceutical University
    China Pharmaceutical University)

  • Min Jin

    (China Pharmaceutical University)

  • Yang Cao

    (China Pharmaceutical University)

  • Hongchao Li

    (China Pharmaceutical University
    China Pharmaceutical University)

Abstract

Background and Objective All oral direct-acting antivirals (DAAs) have shown excellent efficacy and safety in Chinese patients with chronic hepatitis C (CHC). However, the cost of DAAs used to be expensive; therefore, large numbers of patients had no access to DAAs in China. Recently, prices have been greatly reduced. The objective of this study was to evaluate the cost-effectiveness of ledipasvir/sofosbuvir (LDV/SOF), sofosbuvir/velpatasvir (SOF/VEL), elbasvir/grazoprevir (EBR/GZR) and glecaprevir/pibrentasvir (GLE/PIB) in Chinese CHC patients stratified by hepatitis C virus (HCV) genotype (GT), cirrhosis status, and treatment history. Methods On the basis of a Chinese healthcare perspective, a Markov model was constructed to estimate the lifetime costs and health outcomes of patients treated with different DAA regimens. Chinese-specific clinical, cost, and utility inputs were obtained or calculated from published sources and expert opinions. Costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were reported as primary outcomes. Base-case analysis and sensitivity analysis were conducted. Results At a willing-to-pay (WTP) threshold of US$30,081/QALY (calculated by three times the GDP per capita in China), SOF/VEL was cost-effective in patients with HCV GT 1, 3, and 6 infections, and the probabilities that SOF/VEL was cost-effective were 9.7–75.7%, 39.1–63.9%, and 35.6–88.0%, respectively. For GT2 patients, noncirrhotic patients, treatment-naïve patients, and treatment-experienced patients, LDV/SOF was the most cost-effective regimen, and the probabilities of cost-effectiveness for each of these groups was 92.1–99.8%, 89.9–99.0%, 61.6–91.2%, and 99.3–100.0%, respectively below the WTP threshold. The GLE/PIB regimen (12-week duration) was the most cost-effective in cirrhotic patients, whereas the probability of its cost-effectiveness varied with that of EBR/GZR (4.1–93.8% versus 6.2–93.3%) below the WTP threshold. Conclusions Overall, SOF/VEL and LDV/SOF regimens are more likely to be cost-effective among various subgroups of Chinese patients with CHC.

Suggested Citation

  • Pingyu Chen & Min Jin & Yang Cao & Hongchao Li, 2021. "Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 371-387, May.
    • Handle: RePEc:spr:aphecp:v:19:y:2021:i:3:d:10.1007_s40258-020-00623-3
    DOI: 10.1007/s40258-020-00623-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-020-00623-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-020-00623-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Matteo Ruggeri & Federica Romano & Michele Basile & Silvia Coretti & Francesca Romana Rolli & Carlo Drago & Americo Cicchetti, 2018. "Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy," Applied Health Economics and Health Policy, Springer, vol. 16(5), pages 711-722, October.
    2. Guo-Feng Chen & Lai Wei & Jing Chen & Zhong-Ping Duan & Xiao-Guang Dou & Qing Xie & Wen-Hong Zhang & Lun-Gen Lu & Jian-Gao Fan & Jun Cheng & Gui-Qiang Wang & Hong Ren & Jiu-Ping Wang & Xing-Xiang Yang, 2016. "Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data," PLOS ONE, Public Library of Science, vol. 11(6), pages 1-13, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini, 2019. "Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data," PharmacoEconomics, Springer, vol. 37(2), pages 255-266, February.
    2. Yun Lu & Xiuze Jin & Cheng-a-xin Duan & Feng Chang, 2018. "Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China," PLOS ONE, Public Library of Science, vol. 13(4), pages 1-12, April.
    3. Yin Liu & Hui Zhang & Lei Zhang & Xia Zou & Li Ling, 2020. "Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China," IJERPH, MDPI, vol. 17(3), pages 1-13, January.
    4. Ru Han & Clément François & Mondher Toumi, 2021. "Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results," Applied Health Economics and Health Policy, Springer, vol. 19(1), pages 29-44, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:19:y:2021:i:3:d:10.1007_s40258-020-00623-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.